M&A / Deals Vertex buys Crinetics for $10bn in endocrinology drive PharmaphorumVertex has made the largest acquisition in its history, agreeing to buy Crinetics in a $10bn deal that adds an approved therapy for acromegaly.Rare DiseaseRead full story pharminent July 7, 2026 (Last updated: July 8, 2026) Pharmaphorum Vertex has made the largest acquisition in its history, agreeing to buy Crinetics in a $10bn deal that adds an approved therapy for acromegaly. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: EC approves AbbVie’s Tepkinly combination for follicular lymphomaNext: Vera’s TRUTAKNA Wins FDA Accelerated Approval for IgA Nephropathy Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
